IMS Health (IMS) Tops Q4 EPS by 2c

IMS Health (NYSE: IMS) reported Q4 EPS of $0.36, $0.02 better than the analyst estimate of $0.34. Revenue for the quarter came in at $678 million versus the consensus estimate of $679.82 million.

“We closed out the year with another quarter of strong financial performance. Our technology services offerings continue to gain traction with customers, again growing double digits on a constant currency basis,” said Ari Bousbib, chairman and CEO, IMS Health. “We are very pleased with our performance during our first year as a public company and are looking forward to another excellent year in 2015, including the successful completion of the Cegedim asset acquisition, which we now expect to close early in the second quarter.”

2015 Full-Year Guidance

We expect Core IMS Health (excluding the impact of the pending acquisition of Cegedim’s CRM and Strategic Data businesses) to have full-year 2015 constant currency growth of 5 to 6 percent in revenue, 7.5 to 8.5 percent in Adjusted EBITDA, 16 to 19 percent in Adjusted Net Income, and 11 to 14 percent in Adjusted Diluted Earnings per Share. Including the acquisition of Cegedim’s CRM and Strategic Data businesses, which we anticipate will close in April, we expect IMS Health to have full-year 2015 constant currency growth of 19 to 20 percent in revenue, 13 to 14 percent in Adjusted EBITDA, 20 to 23 percent in Adjusted Net Income, and 15 to 18 percent in Adjusted Diluted Earnings per Share; on a reported basis, and assuming current foreign exchange rates hold constant through the end of the year, these growth rates would be 11 to 12 percent for revenue, 5 to 6 percent for Adjusted EBITDA, 8 to 11 percent for Adjusted Net Income, and 4 to 6 percent for Adjusted Diluted Earnings per Share.

For earnings history and earnings-related data on IMS Health (IMS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Reading (RDI) Tops Q2 EPS by 4c